Tilt and decentration of aberration-correcting IOLs affect VA

Article

Aberration-correcting IOLs are more sensitive to decentration and tilt

Aberration-correcting IOLs are more sensitive to decentration and tilt, according to a paper in the Journal of Cataract and Refractive Surgery.

Dr David Madrid-Costa and his team, Optics Department, University of Valencia, Valencia, Spain, completed a cohort study on 10 eyes of 10 patients. Two aspheric aberration-correcting IOLs and two spherical IOLs were tested on all patients. The outcome measures included monocular distance visual acuity at 100%, 50% and 10% and depth of focus.

After centration of the IOLs there were no differences in visual acuity between all four IOLs. However, both aberration-correcting were found to be more sensitive to tilt and decentration than the spherical IOLs.

The results demonstrated that higher residual spherical aberration slightly improved depth of focus and defocus tolerance. Visual quality in the eyes with aspheric aberration-correcting IOLs presented with corneal higher-order aberrations in those who have an average human cornea.

Recent Videos
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
Paulo Antonio Silva, Associate Professor of Ophthalmology at Harvard Medical School
Intraocular Pressure Outcomes Following Suprachoroidal Triamcinolone Acetonide in Patients With Glaucoma, Ocular Hypertension, or Steroid Response
Durga Borkar, MD, MMCi, discusses FAS inhibition with ONL-1204
Theodore Leng, MD, MS, speaks about 12-Month Real-World Clinical and Anatomical Outcomes With Faricimab in Patients With Diabetic Macular Edema:The FARETINA-DME Study
Rishi P. Singh, MD, discussed his presentation on the results from part 1 of the Phase 2/3 SIGLEC trial assessing AVD-104 for GA
Carl C. Awh, MD, FASRS, speaks with Hattie Hayes of Ophthalmology Times Europe
© 2024 MJH Life Sciences

All rights reserved.